


FV519866966US

Atty Dkt. No.: UCSF-129
USSN: 09/817,360

**DECLARATION OF MICHAEL
S. GERMAN
UNDER 37 C.F.R. § 1.132**

Attorney Docket	UCSF-129CIP
First Named Inventor	Michael S. German
Confirmation Number	2345
Application Number	09/817,360
Filing Date	March 20, 2001
Group Art Unit	1635
Examiner Name	Brian Whiteman
Title: <i>Production of pancreatic islet cells and delivery of insulin</i>	

Dear Sir:


I, Michael S. German, do hereby declare as follows:

1. I am the sole inventor of the claimed subject matter of the above-referenced patent application.
2. The inventors of the subject matter claimed in U.S. Patent No. 6,703,220, issued March 9, 2004, are Dr. Joseph Lin and myself.
3. The claims of U.S. Patent No. 6,703,220 are directed to nucleic acids encoding human Ngn3, related compositions and methods of using those nucleic acids to produce a polypeptide. Since Dr. Lin and I both contributed to efforts to identify and clone Ngn3, we are both inventors of the subject matter claimed in U.S. Patent No. 6,703,220.
4. The claims of the above-reference patent application are directed to methods of using neuroendocrine bHLH transcription factors to produce insulin-producing cells.

Atty Dkt. No.: UCSF-129
USSN: 09/817,360

5. Although Dr Lin did contribute to the cloning of Ngn3, he did not contribute to the conception of methods of using neuroendocrine bHLH transcription factors to produce insulin-producing cells. Such methods were solely conceived by me and, as such, I am the sole inventor of the subject matter claimed in the above-referenced patent application. Dr. Lin did not contribute to the conception of such methods and, as such, is not an inventor of the subject matter claimed in the above-referenced patent application.
6. I, Michael S. German, hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title XVIII of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

11/21/04
Date


Michael S. German, M.D.